NEOK Bio
ABL Bio’s $75M bet that two targets are better than one. NEOK is building the most ambitious bispecific ADC pipeline to hit the U.S. clinic — and they already have two INDs cleared by FDA.
US-Based
Clinical-Stage
Bispecific ADC
Oncology
🔭
Company Snapshot
📋
Company Overview
NEOK Bio emerged from stealth in November 2025 with $75M to advance bispecific ADCs — antibody-drug conjugates that hit two tumor targets simultaneously instead of one. The thesis: by requiring co-expression of both antigens, you get tighter tumor selectivity and less off-target toxicity than conventional ADCs.
NEOK001 pairs ROR1 with B7-H3; NEOK002 pairs EGFR with MUC1 — target combinations unlikely to co-occur on healthy tissue. Both cleared FDA IND within 10 weeks of each other. Built on ABL Bio’s Grabody platform and proprietary SYNtecan E™ linker technology, with Phase 1 data expected in 2027.
🧬
Pipeline Overview
NEOK001 — B7-H3 × ROR1 Bispecific ADC in Solid Tumors
First-in-class bispecific ADC. FDA IND cleared January 2026. Phase 1 dose-escalation in advanced solid tumors launching H1 2026. Data expected 2027.
NEOK002 — EGFR × MUC1 Bispecific ADC in Solid Tumors
Second bispecific ADC. FDA IND cleared March 2026 — six weeks after NEOK001. Phase 1 planned Q2 2026. Data expected 2027.
📊
Market Context
The global ADC market crossed $15B in 2025, projected to exceed $30B by 2030 — validated by Pfizer’s $43B Seagen acquisition. NEOK’s target indications (thoracic, GI, gynecological cancers) represent some of oncology’s largest addressable markets, with lung cancer alone accounting for $30B+ in annual therapeutic spend. Bispecific ADCs remain largely unproven clinically, meaning first movers with clean data will command outsized attention from pharma BD teams.
🚀
The Voyager Take
What’s working: Two IND clearances in 10 weeks from a company four months out of stealth — exceptional execution. $75M single-investor Series A from ABL Bio means zero syndicate friction and tight platform-developer alignment.
What’s concerning: Zero clinical data disclosed. Bispecific ADCs are mechanistically elegant but clinically unproven at scale. CEO’s prior company (Effector Therapeutics) folded after a midphase data miss.
What we’re watching for: First Phase 1 dose-escalation safety and PK data in 2027 — that readout will determine whether the dual-targeting thesis translates from preclinical models to patients.
NEOK Bio
| Founded: | 2025 |
| Location: | Palo Alto, CA |
| Stage: | Clinical (IND) |
| Status: | Private |
| Funding: | $75M Series A |
| Lead Investor: | ABL Bio |
Company Leadership
Key Technology
SYNtecan E™ — Proprietary linker-payload technology enabling ADC generation with strong linker stability and superior biophysical properties.
Grabody Platform — ABL Bio’s bispecific antibody engineering platform with multiple clinical-stage programs.
The Biotech Voyager · Company profiles powered by HOUSTON intelligence
